Q2 2025 Management View CEO Kim Kelderman highlighted 9% organic revenue growth for the quarter, driven by strong performance in biopharma end markets, particularly large pharma, which benefited GMP ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

Leeford is shaping the future of healthcare through cutting-edge formulations and a commitment to global quality standards.

Vietnam’s pharmaceutical market is expected to have a year of optimism after experiencing a multicoloured gamut in 2024.

Nepal Ausadhi Limited has been awarded with the Good Manufacturing Practice (GMP) certificate, meeting the World Health ...

Dr Agarwal IPO opened for subscription on January 29 and will end today, January 31 The IPO price band is set at ₹382 to ₹402 per share.

Kolkata: The West Bengal health dept asked a saline manufacturing unit, which is a major supplier to govt hospitals, to stop manufacturing the product.

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Imexpharm Corporation reported VND2,205 billion (US$87.3 million) in net revenue for 2024, marking a 10.6% year-on-year increase.

HYTN will endeavour to amend its licenses and/or certificates, establish a stability program, and implement GMP-compliant processes tailored for vape cartridge production.